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Abstract
Background: Receptor tyrosine kinases promote tumor progression in many cancers, although oncologic activation
differs between diffuse-type gastric cancer (DGC) and intestinal-type gastric cancer (IGC). Fibroblast growth factor
receptor (FGFR) is one RTK, and we previously reported the clinical significance of FGFR1, 2, 3, and 4 in gastric
cancer. The aim of the present study was to reevaluate the clinical significance of FGFR1–4 expression separately in
DGC and IGC.
Methods: Tumor samples, including 109 DGCs and 100 IGCs, were obtained from patients who underwent gastrectomy
between 2003 and 2007 in our institution. The expression levels of FGFR1, 2, 3, and 4 were measured in the tumors by
immunohistochemical analysis.
Results: In DGC, high expression of FGFR1, FGFR2, or FGFR4 was significantly associated with the depth of invasion,
lymph-node metastasis, pathological stage, and distant metastasis or recurrent disease. Patients with high expression of
FGFR1, FGFR2, or FGFR4 had significantly poorer disease-specific survival (DSS) (p = 0.009, p = 0.001, and p = 0.023,
respectively). In IGC, only FGFR4 expression was significantly associated with factors relative to tumor progression
and with shorter DSS (p = 0.012).
Conclusion: In conclusion, high FGFR4 expression correlated with tumor progression and survival in both DGC
and IGC, whereas high expression of FGFR1 and 2 correlated with tumor progression and survival in only DGC.
Keywords: Fibroblast growth factor receptor 1, Fibroblast growth factor receptor 2, Fibroblast growth factor
receptor 3, Fibroblast growth factor receptor 4, Gastric cancer, Immunohistochemistry
Background
Gastric cancer (GC) is categorized into three types based
on Lauren’s pathological classification: diffuse type,
intestinal type, and mixed type [1]. Diffuse-type gastric
cancer (DGC) is associated with more advanced
disease stage and poorer survival than intestinal-type
gastric cancer (IGC) [2, 3]. It is well known that pro-
tein or gene overexpression of receptor tyrosine
kinases (RTKs) correlates with tumor progression and
poor survival in GC [4, 5]. The immunohistochemical
overexpression of human epidermal growth factor
receptor 2 (HER2), one of the RTKs, was detected
more frequently in IGC than in DGC [6]. Comprehensive
genomic analyses performed in The Genomic Cancer
Atlas (TGCA) project revealed different genomic alter-
ations of RTKs between DGC and IGC [7]. Therefore,
the impact of RTK overexpression on clinical outcomes
might differ between DGC and IGC.
The fibroblast growth factor receptor (FGFR) family
comprises one type of RTK that regulates fundamental
developmental pathways by interacting with fibroblast
growth factors (FGFs). FGF signaling participates in
several biological functions in the adult organism, including
regulation of angiogenesis and wound repair. FGFRs are
expressed on a number of different cell types and regulate
key cell activities, such as proliferation, survival, migration,
and differentiation [8]. FGFR2 gene amplification was
initially found in a GC cell line originating from DGC
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with the poorest prognosis [9]. Gene amplification or
protein overexpression of FGFR2 has been reported in
GC, leading to poor outcomes [10]. Moreover, GC cell
lines presenting with FGFR2 amplification are highly
sensitive to inhibition of FGFR signaling by tyrosine
kinase inhibitors and monoclonal antibodies in preclinical
models [11, 12]. FGFR2 has thus attracted considerable
attention as a novel therapeutic candidate for the devel-
opment of targeted anticancer agents [13].
We previously reported the relations of the immuno-
histochemical expressions of FGFR1–4 to tumor pro-
gression or poor survival in GC. However, tumors were
classified into differentiated and undifferentiated types
based on the World Health Organization pathological
classification in the previous study and were not classi-
fied according to Lauren’s classification [14]. The present
study was designed to reevaluate the clinical significance
of FGFR1–4 expression separately in DGC and IGC




GC tissue samples were obtained from 222 patients with
primary gastric adenocarcinoma who underwent surgical
resection between January 2003 and December 2007 in
our institution. Each tumor was examined pathologically
and classified according to the tumor–node–metastasis
staging system recommended by the Union for Inter-
national Cancer Control (UICC). Of the 222 patients,
109, 100, and 13 tumors were pathologically diagnosed
as DGC, IGC, and mixed-type GC, respectively. We
excluded the 13 patients with mixed-type GC from the
present study. All patients were evaluated for recurrent
disease by diagnostic imaging (computed tomography,
ultrasonography, magnetic resonance imaging, and endos-
copy) every 3 to 6 months. The median follow-up was
61 months (range, 4 to 111 months). HER2 status was
evaluated by pathologists in our institution and scored
according to standardized assessment criteria [15].
Immunostaining of the FGFR family
The detailed method used to perform immunohistochemical
analysis was described in our previous report [14]. Represen-
tative formalin-fixed, paraffin-embedded tissue blocks were
sliced into 4-μm-thick sections. After deparaffinization and
rehydration, antigen retrieval was performed. Subsequently,
endogenous peroxidase and non-specific binding were
blocked. The slides were incubated with the primary
polyclonal rabbit antibodies, including anti-FGFR1 (di-
lution, 1:100), anti-FGFR2 (dilution, 1:300), anti-FGFR3
(dilution, 1:500), and anti-FGFR4 (dilution, 1:100), in 1%
bovine serum albumin/phosphate-buffered saline over-
night at 4 °C. All primary antibodies (named sc-121, 122,
123, and 124 for FGFR1, 2, 3, and 4, respectively) were
purchased from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA, USA). The sections were then incubated with
secondary antibodies, Histofine Simple Stain MAX PO
(Multi) (Nichirei Co., Tokyo, Japan), for 30 min at room
temperature. The chromogen substrate was 3,3′-diamino-
benzidine tetrahydrochloride solution (Histofine Simple
Stain DAB solution, Nichirei Co.). Subsequently, the
sections were counterstained with Mayer’s hematoxylin
(Wako, Tokyo, Japan). Negative controls were treated
similarly, except that the antibodies were replaced by
normal rabbit IgG (Santa Cruz Biotechnology, Inc.).
Interpretation of immunostaining
The assessment of FGFR1–4 staining was based on a
previous study of FGFR2 [5], although the criteria were
modified slightly and simplified. The staining intensity
was scored into three grades as follows: 0, no staining; 1,
Fig. 1 Immunostaining for fibroblast growth factor receptor (FGFR)1,
FGFR2, FGFR3, and FGFR4. Representative primary gastric carcinomas
exhibiting high expression for (a) FGFR1, (b) FGFR2, (c) FGFR3, and
(d) FGFR4 in diffuse-type gastric cancer. Representative primary
gastric carcinomas exhibiting high expression for (e) FGFR1, (f)
FGFR2, (g) FGFR3, and (h) FGFR4 in intestinal-type gastric cancer.
Magnification, ×400
Inokuchi et al. World Journal of Surgical Oncology  (2017) 15:2 Page 2 of 9
weakly positive; and 2, moderately or strongly positive.
The staining extent (positive frequency) was also scored
into three grades according to the percentage of stained
tumor cells as follows: 0, <10%; 1, 10% to 50%; and 2, >50%
stained cells. For the statistical analysis, composite scores
were calculated by addition of the intensity and extent
scores. Composite scores of ≥3 were defined as high
expression, and scores of <3 as low expression. Two
investigators who were blinded to the clinical out-
comes separately counted the stained cancer cells. Any
disagreements between the two investigators were re-
solved by reassessment and consensus.
Statistical analysis
Categorical data were compared with the use of the
chi-square test or Fisher’s exact test, as appropriate.
Kaplan-Meier curves were plotted to assess the effects
of FGFR expression on disease-specific survival (DSS),
and different DSS curves were compared using the log-
rank test. Multivariate proportional Cox models were used
to assess the prognostic significance of FGFR and of factors
significantly associated with DSS. Values of p < 0.05 were
considered to indicate statistical significance. All analyses
were performed with the statistical software package SPSS
22 (SPSS Japan Inc., Tokyo, Japan).
Table 1 Clinicopathological factors and expressions of FGFR1 to FGFR4 in DGC
FGFR1 FGFR2 FGFR3 FGFR4
Low High p Low High p Low High p Low High p
n 69 40 56 53 44 65 21 88
Age (years)
< 65 61 45 16 0.011 37 24 0.029 24 37 0.81 15 46 0.11
≥ 65 48 24 24 19 29 20 28 6 42
Gender
Female 40 25 15 0.90 22 18 0.56 11 29 0.037 8 32 0.88
Male 69 44 25 34 35 33 36 13 56
Main location
Middle or lower 83 54 29 0.50 46 37 0.13 28 55 0.012 16 67 1.00
Upper 26 15 11 10 16 16 10 5 21
Depth of invasion
Early (T1) 35 29 6 0.004 26 9 0.001 18 17 0.11 12 23 0.006
Advanced (T2/3/4) 74 40 34 30 44 26 48 9 65
LN metastasis
Negative (N0) 45 35 10 0.009 30 15 0.007 19 26 0.74 16 29 <0.001
Positive (N1/2/3) 64 34 30 26 38 25 39 5 59
Stage
I 43 36 7 <0.001 30 13 0.002 21 22 0.15 16 27 <0.001
II/III/IV 66 33 33 26 40 23 43 5 61
Distant metastasis or recurrence
Negative 67 50 17 0.002 43 24 0.001 28 39 0.70 18 49 0.01
Positive 42 19 23 13 29 16 26 3 39
Peritoneal dissemination
Negative 82 58 24 0.005 46 36 0.086 35 47 0.39 18 64 0.22
Positive 27 11 16 10 17 9 18 3 24
Hematogenous metastasis
Negative 106 67 39 1.00 56 50 0.11 42 64 0.56 21 85 1.00
Positive 3 2 1 0 3 2 1 0 3
HER2 score
0–1 106 68 38 0.56 55 51 0.61 43 63 1.00 21 85 1.00
2–3 3 1 2 1 2 1 2 0 3
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Results
DGC
Among the 109 DGC tumors studied, high expression of
FGFR1, 2, 3, and 4 was shown by 40 (37%), 53 (49%), 65
(60%), and 88 (81%) tumors, respectively (Fig. 1). In a
previous study, FGFRs were not stained or only weakly
stained in normal gastric epithelium [14]. The relations
of various clinicopathological factors to the expression
levels of FGFR1–4 are summarized in Table 1. High
expression levels of FGFR1, 2, and 4 were significantly
associated with the depth of invasion (early cancer vs.
advanced cancer), lymph-node metastasis (negative vs.
positive), tumor stage (stage I vs. stage II or more ad-
vanced), and distant metastasis or recurrence (negative
vs. positive). Only FGFR3 expression did not correlate
with those factors. High FGFR1 expression significantly
correlated with peritoneal dissemination, and high
FGFR2 expression tended to be associated with peritoneal
dissemination. Few DGC tumors were associated with
hematogenous metastasis (liver or lung metastasis) or
HER2 score.
Patients whose tumors showed high expression of
FGFR1, FGFR2, or FGFR4 had significantly poorer DSS
on univariate analysis (p = 0.009, p = 0.001, and p = 0.023,
respectively; Fig. 2). FGFR3 was not significantly associ-
ated with DSS. Median follow-up times did not differ
significantly between high and low expression of any
FGFR. Cox proportional-hazards regression analysis of
DSS was performed, with adjustment for the following
clinical variables shown to be prognostic factors on uni-
variate analysis: age (≥65 vs. <65), main location (middle
or lower vs. upper), depth of tumor invasion, lymph-node
metastasis, and FGFR1, FGFR2, and FGFR4 expression
(low vs. high). However, multivariate analysis indicated
that expression levels of FGFR1–4 were not significant
independent prognostic factors for DSS (Table 2). The
depth of invasion (hazard ratio [HR] 8.9, 95% confi-
dence interval [CI] 1.2–68, p = 0.034) and lymph-node
metastasis (HR 6.1, 95% CI 1.8–21, p = 0.004) were in-
dependent prognostic factors for DSS.
IGC
Among the 100 IGC tumors, high expression of FGFR1,
2, 3, and 4 was shown by 38 (38%), 64 (64%), 76 (76%),
and 81 (81%) tumors, respectively (Fig. 1). The relations
of clinicopathological variables to the expression levels
of FGFR1–4 are summarized in Table 3. Only high
FGFR4 expression was significantly associated with the
following factors closely related to tumor growth: depth
of invasion, lymph-node metastasis, tumor stage, and
distant metastasis or recurrence. However, FGFR expres-
sion levels did not correlate with the site of recurrence.
A B
C D
Fig. 2 Survival of patients with diffuse-type gastric cancer. Kaplan-Meier curves for the disease-specific survival of patients with expression of (a)
fibroblast growth factor receptor (FGFR)1, (b) FGFR2, (c) FGFR3, and (d) FGFR4
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FGFR1, 2, and 3 were not significantly associated with
any clinicopathological variable. HER2 score did not
significantly correlate with any FGFR.
Patients whose tumors showed high FGFR4 expression
had significantly shorter DSS than those with low FGFR4
expression on univariate analysis (p = 0.012); expression
levels of the other FGFRs did not significantly correlate
with DSS (Fig. 3). Median follow-up times did not differ
significantly between high and low expression of any FGFR.
Multivariate analysis using a Cox regression hazard model
could not be performed, because no patient with low
expression of FGFR4 died of GC.
Discussion
Our results suggested that the clinical significance of the
immunohistochemical expression of FGFRs might differ
between DGC and IGC. High FGFR4 expression was
frequently found in DGC and even in IGC and was
significantly related to tumor progression and metastasis in
both types of GC. Previous studies showed that overexpres-
sion of FGFR4 protein or FGFR4 mRNA correlated with
shorter survival in GC [16, 17]. However, FGFR4 protein
was not significantly associated with clinicopathological
factors such as tumor depth or lymph-node metastasis
[16, 18]. FGFR4 protein overexpression was shown to
be an independent prognostic factor in non-small cell
lung cancer [19] and colorectal cancer [20]. In addition,
the FGFR4 Arg388 allele, leading to high FGFR protein
expression, correlated with shorter survival in GC [21].
In an in vitro study, FGFR4 showed different intracellular
sorting patterns from those of FGFR1–3. FGFR4 and its
bound ligand were sorted mainly to the recycling com-
partment and could prolong signaling, whereas FGFR1, 2,
and 3 with their ligands were sorted mainly to degradation
in lysosomes [22]. Colorectal cancer cell lines cocultured
with tumor-associated fibroblasts (TAF) induced signifi-
cant overexpression of FGFR4, but not of other FGFRs
[23]. In addition, FGFR4 plays crucial roles in TAF-in-
duced epithelial-to-mesenchymal transition [23]. Thus,
FGFR4 might play a different role from other FGFRs in
malignant tumors.
In the present study, high FGFR2 expression significantly
correlated with tumor progression and survival in only
DGC, and such expression was likely to be associated with
peritoneal dissemination. On the basis of whole-genome
sequence data, many IGCs were classified as chromo-
somally unstable tumors, in which RTK-RAS signal
transduction pathway is often activated [7]. Moreover,
FGFR2 amplification was mutually exclusive from the
amplification of other RTKs [4]. The overexpression of
HER2 or c-MET was observed more frequently in IGC
than in DGC [6, 24], suggesting that a signaling pathway
activated by these RTKs might have a critical role in the
progression and prognosis of IGC. HER2 overexpression
was often found in IGC without significant association of
FGFRs in this study, and our results might support those
of another study reporting exclusive RTK expression [5].
In a previous review, FGFR2 protein overexpression on
immunohistochemical analysis was found more frequently
in undifferentiated GC than in differentiated GC [10].
Another study reported that GC tumors with FGFR2
protein overexpression were significantly more common
in DGC than in IGC [25]. A further study showed that
FGFR2 protein overexpression was significantly associated
with poor survival and peritoneal dissemination in GC [5].
These findings suggest that FGFR2 can contribute to the
development of DGC or undifferentiated GC, often in
association with peritoneal dissemination. However, FGFR2
overexpression was similarly observed in differentiated GC
and undifferentiated GC in a study of 950 Japanese patients
[5]. FGFR2 gene amplification was initially detected in a
scirrhous-type GC cell line [26]. Similar presences of
Table 2 Prognostic factors for DSS on multivariate analysis in DGC
Univariate (log-rank) Multivariate
5-yr DSS (%) p HR 95% CI p
Age (years)
< 65 73 1





Middle or lower 72 1
Upper 41 0.010 1.8 0.90–3.4 0.097
Depth of invasion
Early (T1) 97 1
Advanced (T2/3/4) 49 <0.001 8.9 1.2-68 0.034
LN metastasis
Negative (N0) 95 1
Positive (N1/2/3) 43 <0.001 6.1 1.8–21 0.004
FGFR1
Low 74 1
High 50 0.009 1.2 0.60–2.3 0.66
FGFR2
Low 80 1






High 60 0.023 1.1 0.32–3.7 0.89
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FGFR2 amplification in DGC and IGC or in undifferenti-
ated GC and differentiated GC have been reported by some
studies; however, such amplification was not often found in
GC (1.8 to 9.3%) [4, 27–32]. FGFR2 gene amplification was
significantly related to poor survival in GC [27–31]. A
meta-analysis including various types of cancers showed
that FGFR2 amplification significantly correlated with poor
survival [33]. FGFR2 inhibitors are being studied as anti-
cancer agents against FGFR2-amplified GC in ongoing clin-
ical trials [10].
High FGFR1 protein expression was significantly asso-
ciated with poor survival and the presence of peritoneal
dissemination in only DGC in the present study. To our
knowledge, no previous study has assessed the clinical
significance of FGFR1 protein expression in DGC. Ampli-
fication of the FGFR1 gene was a rare but noticeable event
that was found in 2% (6 of 293) of GCs and was associated
with distant metastasis and poor survival in another study,
although tumors with FGFR1 amplification were found in
IGC, DGC, and mixed-type GC [34]. FGFR1 protein
expression of ≥1% in tumors was associated with poor
survival in patients with breast cancer [35]. FGFR1 amplifi-
cation was also associated with poor survival in esophageal
cancer [36], breast cancer [37], and squamous-cell lung
cancer [38]. In a study of colorectal cancer, the copy number
gain of FGFR1 significantly correlated with worse outcomes
Table 3 Clinicopathological variables and expressions from FGFR1 to FGFR4 in IGC
FGFR1 FGFR2 FGFR3 FGFR4
Low High p Low High p Low High p Low High p
n 62 38 36 64 24 76 19 81
Age (years)
< 65 32 19 13 0.71 10 22 0.50 7 25 0.73 9 23 0.11
≥ 65 68 43 25 26 42 17 51 10 58
Gender
Female 13 5 8 0.073 3 10 0.37 3 10 1.00 1 12 0.45
Male 87 57 30 33 54 21 66 18 69
Main location
Middle or lower 84 53 31 0.61 32 52 0.32 19 65 0.53 15 69 0.50
Upper 16 9 7 4 12 5 11 4 12
Depth of invasion
Early (T1) 49 34 15 0.14 22 27 0.069 12 37 0.91 17 32 <0.001
Advanced (T2/3/4) 51 28 23 14 37 12 39 2 49
LN metastasis
Negative (N0) 66 42 24 0.64 26 40 0.33 16 50 0.94 17 49 0.016
Positive (N1/2/3) 34 20 14 10 24 8 26 2 32
Stage
I 60 40 20 0.24 25 35 0.15 15 45 0.77 18 42 0.001
II/III/IV 40 22 18 11 29 9 31 1 39
Distant metastasis or recurrence
Negative 80 53 27 0.080 31 49 0.25 17 63 0.24 19 61 0.01
Positive 20 9 11 5 15 7 13 0 20
Peritoneal dissemination
Negative 93 59 34 0.42 34 59 1.00 21 72 0.35 19 74 0.34
Positive 7 3 4 2 5 3 4 0 7
Hematogenous metastasis
Negative 90 56 34 1.00 34 56 0.32 22 68 1.00 19 71 0.20
Positive 10 6 4 2 8 2 8 0 10
HER2 score
0–1 84 50 34 0.24 30 54 0.89 19 65 0.53 18 66 0.29
2–3 16 12 4 6 10 5 11 1 15
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[39]. The clinical significance of FGFR3 protein expression
differs somewhat among tumor types. FGFR3 protein
expression was not associated with any clinicopathological
feature in the present study, although few studies of FGFR3
expression in gastrointestinal cancers have been re-
ported. No relation was found between FGFR3 protein
expression and clinicopathological features in breast
cancer [40]. FGFR3 protein expression did not correlate
with survival in urothelial carcinoma of the bladder [41].
In contrast, FGFR3 protein expression was significantly
associated with shorter survival in multiple myeloma [42].
In our study, FGFRs were expressed mainly in the cyto-
plasm and partially even in the nucleus. FGFR2 and 4 were
mainly found in the cytoplasm of GC cells in other studies
[5, 17], which was supported by our results. Epidermal
growth factor receptor (EGFR) or HER2 was expressed
mainly in the membrane on immunohistochemical ana-
lysis, although other RTKs, such as HER3 or cMET, were
found not only in the membrane but also in the cytoplasm
or nucleus of GC cells [43, 44]. EGFR was also transported
in the nucleus, and nuclear localized EGFR is strongly
associated with disease progression and worse overall sur-
vival in numerous cancers [45]. The status of Helicobacter
pylori infection was not investigated in this study. How-
ever, infection with CagA-positive strains of Helicobacter
pylori was significantly associated with the presence of GC
in both IGC and DGC [46].
Conclusion
In conclusion, the protein expressions of FGFR1–4 had
different impacts on clinical outcomes in DGC and IGC.
High FGFR4 expression correlated with tumor progression
and survival in both types of GC, although FGFR1 and 2
correlated with these variables in only DGC. Therefore,
FGFR inhibitors might be more effective for DGC than
IGC.
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